Fighting for scraps
Back when BGM ruled the glucose monitoring world the market was dominated by two major players LifeScan and Roche, two minor players Bayer and Abbott and then everyone else. The majors controlled over 65% of the market, the minors another 15%-20% leaving everyone else fighting for about 15% or less of the overall market. It wasn’t much different in the insulin pump market which was basically the domain of MiniMed controlling 70%+ of the that market.
Fast forward to today and the technology may have changed but market shares haven’t. Dexcom and Abbott effectively have a duopoly . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.